Outpatient Treatment of SARS-CoV-2 Infection to Prevent COVID-19 Progression 

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Cohen, Myron S
    • Affiliation: School of Medicine
  • Wohl, David A
    • Affiliation: School of Medicine
  • Fischer, William A, II
    • Affiliation: School of Medicine
  • Smith, David J
    • Other Affiliation: University of California San Diego
  • Eron, Joseph J
    • Affiliation: School of Medicine
Abstract
  • As of March 2021, COVID-19 has caused more than 123 million infections, and almost 3 million deaths worldwide. Dramatic advances have been made in vaccine development and non-pharmaceutical interventions to stop the spread of infection. But treatments to stop the progression of disease are limited. A wide variety of "repurposed" drugs explored for treatment of COVID-19 have had little or no benefit. More recently, intravenous monoclonal antibody (mAb) combinations have been authorized by the US FDA for emergency use (EUA) for outpatients with mild to moderate COVID-19 including some active against emerging SARS-COV-2 variants of concern (VOC). Easier to administer therapeutics including intramuscular and subcutaneous mAbs and oral antivirals are in clinical trials. Reliable, safe, effective COVID-19 treatment for early infection in the outpatient setting is of urgent and critical importance. Availability of such treatment should lead to reduced progression of COVID-19.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Clinical Infectious Diseases
Version
  • Postprint
ISSN
  • 1058-4838
Publisher
  • Oxford University Press

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details ciab494.pdf 2021-06-07 Public Download